

AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks


IN BRIEF: Hutchmed tumor drug qualifies for formal review by EU agency


(Sharecast News) - Hutchmed China announced the first commercial sale in China of 'Orpathys', or savolitinib, on Tuesday, which is its "oral, potent, ...


TRADING UPDATES: Smiths gets Euros sticker boost; Hotel Chocolat grows


TRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays


TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free


TRADING UPDATES: Topps Tiles improves as curbs ease; Bermele makes buy


IN BRIEF: Hutchmed launches global offering for 104 million shares